ACOG 委员会意见第 752 号摘要:产前和围产期人类免疫缺陷病毒检测
该委员会意见强调,早期识别和治疗所有感染 HIV 的孕妇是预防新生儿感染和改善妇女健康的最佳途径;筛查应在告知所有孕妇 HIV 筛查为常规产前检查一部分且可选择退出后进行;对高风险孕妇建议在妊娠晚期(最好 36 周前)重复检测;未检测或状态不明者应在分娩或产后立即快速检测,结果应在 1 小时内可得;快速检测阳性应立即启动抗逆转录病毒预防并等待补充试验,确诊后应转诊 HIV 专科共同管理。
要点
- 所有孕妇应接受 HIV 筛查,采用选择退出方式,作为常规产前检查的一部分。
- 高风险孕妇应在妊娠晚期(最好 36 周前)重复 HIV 检测。
- 未检测或 HIV 状态不明者应在分娩或产后立即快速检测,结果 1 小时内可得。
核心结论
- 早期识别和治疗所有感染 HIV 的孕妇是预防新生儿感染和改善妇女健康的最佳方法。
- 新证据提示,在感染过程中早期启动抗逆转录病毒治疗对 HIV 感染者有益,并减少对未感染伴侣的性传播率。
研究设计与样本
- 美国妇产科医师学会(ACOG)发布的委员会意见。
主要发现
- 采用选择退出方式 HIV 检测应成为孕前和妊娠期尽可能早期常规保健组成部分。
- 对初始 HIV 抗体检测阴性且已知高风险、在孕妇 HIV 年发病率至少 1/1000 的机构接受保健、被监禁、居住在 HIV 发病率升高地区或有急性 HIV 感染体征和症状的孕妇,建议在妊娠晚期(最好 36 周前)重复检测。
- 对妊娠期未检测或 HIV 状态不明者,应在分娩或产后立即采用选择退出方式快速筛查,结果应在 24 小时内可得且在 1 小时内报告。
- 若分娩时快速 HIV 检测结果有反应,应立即启动抗逆转录病毒预防,同时等待补充试验结果。
- 若确诊 HIV 感染,应将妇女转诊至 HIV 专科医生处进行持续保健和共同管理。
关键数值与推荐
- 筛查应在告知所有孕妇 HIV 筛查为推荐且将作为常规产前检查的一部分(除非拒绝)后进行(选择退出筛查)。
- 建议对初始 HIV 抗体检测阴性且符合高风险条件的孕妇在妊娠晚期(最好 36 周前)重复 HIV 检测。
- 对妊娠期未检测或 HIV 状态不明者,应在分娩或产后立即采用选择退出方式快速筛查,结果应在 24 小时内可得且在 1 小时内报告。
- 若分娩时快速 HIV 检测有反应,应立即启动抗逆转录病毒预防,同时等待补充试验结果。
- 若确诊 HIV 感染,应将妇女转诊至 HIV 专科医生处进行持续保健和共同管理。
临床怎么用
- 所有孕妇应在孕前和妊娠期尽早接受 HIV 筛查,采用选择退出方式。
- 对符合高风险条件的孕妇,在妊娠晚期(最好 36 周前)重复 HIV 检测。
- 对妊娠期未检测或 HIV 状态不明者,在分娩或产后立即快速检测,确保结果 1 小时内可得。
- 分娩时快速检测有反应者,立即启动抗逆转录病毒预防并等待补充试验。
- 确诊 HIV 感染者转诊至 HIV 专科医生处共同管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the enormous advances in the prevention of perinatal transmission of human immunodeficiency virus (HIV), it is clear that early identification and treatment of all pregnant women with HIV is the best way to prevent neonatal infection and also improve women's health. Furthermore, new evidence suggests that early initiation of antiretroviral therapy in the course of infection is beneficial for individuals infected with HIV and reduces the rate of sexual transmission to partners who are not infected. Screening should be performed after women have been notified that HIV screening is recommended for all pregnant patients and that they will receive an HIV test as part of the routine panel of prenatal tests unless they decline (opt-out screening). Human immunodeficiency virus testing using the opt-out approach, which is currently permitted in every jurisdiction in the United States, should be a routine component of care for women during prepregnancy and as early in pregnancy as possible. Repeat HIV testing in the third trimester, preferably before 36 weeks of gestation, is recommended for pregnant women with initial negative HIV antibody tests who are known to be at high risk of acquiring HIV infection; who are receiving care in facilities that have an HIV incidence in pregnant women of at least 1 per 1,000 per year; who are incarcerated; who reside in jurisdictions with elevated HIV incidence; or who have signs and symptoms consistent with acute HIV infection (eg, fever, lymphadenopathy, skin rash, myalgias, arthralgias, headache, oral ulcers, leukopenia, thrombocytopenia, or transaminase elevation). Rapid screening during labor and delivery or during the immediate postpartum period using the opt-out approach should be done for women who were not tested earlier in pregnancy or whose HIV status is otherwise unknown. Results should be available 24 hours a day and within 1 hour. If a rapid HIV test result in labor is reactive, antiretroviral prophylaxis should be immediately initiated while waiting for supplemental test results. If the diagnosis of HIV infection is established, the woman should be linked into ongoing care with a specialist in HIV care for comanagement.
引用
- ACOG Committee Opinion No. 752 Summary: Prenatal and Perinatal Human Immunodeficiency Virus Testing. Obstet Gynecol. 2018. PMID: 30134421. doi:10.1097/AOG.0000000000002829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。